Burning Rock Biotech Limited (NASDAQ:BNR) shares traded higher over the last trading session, gaining 3.74% on 05/20/21. The shares fell to a low of $35.51 before closing at $37.45. Intraday shares traded counted 0.66 million, which was -95.26% lower than its 30-day average trading volume of 339.66K. BNR’s previous close was $36.10 while the outstanding shares total 104.22M. The stock’s Relative Strength Index (RSI) is 72.51, with weekly volatility at 10.73% and ATR at 2.23. The BNR stock’s 52-week price range has touched low of $18.64 and a $39.75 high.
Investors have identified the Diagnostics & Research company Burning Rock Biotech Limited as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $3.45 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Having a look at the company’s valuation, the company is expected to record -0.55 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on BNR sounds very interesting.
Is the stock of BNR attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 0.13%.
3 out of 3 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Burning Rock Biotech Limited. 0 analysts has assigned a Sell rating on the BNR stock. The 12-month mean consensus price target for the company’s shares has been set at $23.22.